PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration and development agreement with the Institute of Technology on Immunobiologicals (Bio-Manguinhos) of the Oswaldo Cruz Foundation (Fiocruz) in Brazil to develop a COVID-19 vaccine usi
January 5, 2021 Emergex Vaccines has signed a collaboration and development agreement with the Institute of Technology and Immunobiologicals of the Oswaldo Cruz Foundation in Brazil to develop a COVID-19 vaccine using Emergex s next-generation synthetic T-cell vaccine technology.
The U.K.-based biotechnology company Emergex develops synthetic set point vaccines that prime the T-cell immune response to address viral and bacterial infections.
Under the agreement, both parties will work together to advance immunotherapeutic programs, including a vaccine candidate for COVID-19, through regulatory pathways of the Brazilian National Health Service. Emergex will also support studies, including clinical trials, and to manufacture, market, promote, and distribute certain infectious diseases vaccines within the National Health Service of Brazil.
News Category Global Banking & Finance Reviews
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
PRESS RELEASE
Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
Agreement provides a framework for future clinical trials, manufacturing, sales and marketing, and distribution within the National Health Service of Brazil
Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions
Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces that it has signed a collaboration an